Abstract
We designed and evaluated a new class of molecules, nitrosylated α-adrenergic receptor antagonists, as potential agents for the treatment of impotence. In in vitro studies with human and rabbit corpus cavernosum strips in organ chambers, the α-adrenergic receptor antagonists (α-ARAs) moxisylyte and yohimbine and their corresponding nitrosylated compounds, SNO-moxisylyte (NMI-221) and SNO-yohimbine (NMI-187), concentration-dependently relaxed endothelin-induced contraction. The nitrosylated compounds were significantly more potent than the parent α-ARA. In human tissues, the specific phosphodiesterase type 5 inhibitor zaprinast potentiated the relaxing effects of the nitrosylated compounds. Only nitrosylated compounds induced accumulation of cyclic GMP in rabbit corpus cavernosum strips. Yohimbine and NMI-187 demonstrated a potent α2-blocking activity, with no significant differences in pA2 values (8.9 versus 8.2, respectively). Moxisylyte and NMI-221 showed moderate potency in antagonizing phenylephrine contraction, with comparable pA2 values for both molecules (6.5 versus 6.6, respectively). α-Adrenergic receptor-binding studies showed similar binding affinities for the α-ARA and their corresponding nitrosylated compounds. In vivo, intracavernosal injection of nitrosylated molecules caused greater increases in intracavernosal pressure (NMI-221 versus moxisylyte) that were more long lasting than those of moxisylyte or yohimbine. There were no significant differences between nitrosylated and non-nitrosylated compounds in the magnitude of systemic mean arterial pressure decrease after intracavernosal injection. α-ARA and the nitrosylated compounds showed no pain-inducing activity as evaluated with the paw-lick model in mice. In summary, nitrosylated α-ARA have the dual functionalities of nitric oxide donors and α-ARA. These drugs induced penile erection in animals, suggesting their possible therapeutic value as agents for the local pharmacological treatment of impotence.
Footnotes
-
Send reprint requests to: Iñigo Sáenz de Tejada, M.D., Fundación para la Investigación y el Desarrollo en Andrologı́a C/Antonio Robles, 4-9°C, 28034 Madrid, Spain. E-mail: isaenz{at}ntserver.coronadoserv.com
-
↵1 This work was partially supported by a grant from NitroMed Inc.
- Abbreviations:
- NO
- nitric oxide
- α-ARA
- α-adrenergic receptor antagonist
- α-ARAs
- PGE1, prostaglandin E1
- DMSO
- dimethyl sulfoxide
- PDE
- phosphodiesterase
- PPP
- platelet-poor plasma
- DAM
- desacetylmoxisylyte
- Received October 26, 1998.
- Accepted March 2, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|